
CLAIMS

1. Use of a FAK inhibitor defined by formula I or a pharmaceutically acceptable salt or hydrate thereof in the manufacture of a medicament for treating or preventing pulmonary fibrosis in a patient in need thereof:



Formula I.

2. The use according to claim 1 wherein the FAK inhibitor is a tartrate salt.

3. The use according to claim 1 or claim 2 wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF)

4. The use according to claim 1 or claim 2 wherein the pulmonary fibrosis is associated with infection with a coronavirus.